Get started
BRISTOL-MYRS SQUIBBRISTOL-MYRS SQUIBBRISTOL-MYRS SQUIB

BRISTOL-MYRS SQUIB

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

BRM chart


Full chart

Key facts today


Bristol Myers Squibb's Opdivo and Yervoy combo received FDA priority review for first-line colorectal cancer treatment, targeting patients aged 12 and older, with a decision due by June 23.
Analyze the impactAnalyze the impact

BRM upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪101.86 B‬ CHF
Dividend yield (indicated)
4.44%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.020 CHF
Net income (FY)
‪−8.13 B‬ CHF
Revenue (FY)
‪43.87 B‬ CHF
Shares float
‪2.03 B‬
Beta (1Y)
−0.03

Employees


Employees (FY)
‪34.1 K‬
Change (1Y)
0
Revenue / Employee (1Y)
‪1.29 M‬ CHF
Net income / Employee (1Y)
‪−238.32 K‬ CHF

About Bristol-Myers Squibb Company


Sector
Health Technology
CEO
Christopher S. Boerner
Headquarters
Princeton
Website
bms.com
Founded
1933
FIGI
BBG006TLNGL4
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BRM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BRM highest yielding bonds


C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
7.10%
Maturity date
Nov 15, 2047
US110122DS4
BRIST.MYERS 20/50
Yield to maturity
7.06%
Maturity date
Nov 13, 2050
US110122DR6
BRIST.MYERS 20/40
Yield to maturity
6.50%
Maturity date
Nov 13, 2040
US110122DX3
BRIST.MYERS 22/62
Yield to maturity
6.41%
Maturity date
Mar 15, 2062
C
BMY4036425
Celgene Corporation 5.25% 15-AUG-2043
Yield to maturity
6.40%
Maturity date
Aug 15, 2043
C
BMY4124214
Celgene Corporation 4.625% 15-MAY-2044
Yield to maturity
6.38%
Maturity date
May 15, 2044
US110122DW5
BRIST.MYERS 22/52
Yield to maturity
6.33%
Maturity date
Mar 15, 2052
C
BMY4275603
Celgene Corporation 5.0% 15-AUG-2045
Yield to maturity
6.24%
Maturity date
Aug 15, 2045
BMY3883364
Bristol-Myers Squibb Company 3.25% 01-AUG-2042
Yield to maturity
6.21%
Maturity date
Aug 1, 2042
C
BMY4597874
Celgene Corporation 4.55% 20-FEB-2048
Yield to maturity
6.19%
Maturity date
Feb 20, 2048
US110122DV7
BRIST.MYERS 22/42
Yield to maturity
6.10%
Maturity date
Mar 15, 2042

Explore more bonds 

Sparks


Curated watchlists where BRM is featured.

See all sparks 

Frequently Asked Questions


The current price of BRM is 50.623 CHF — it has decreased by −7.11% in the past 24 hours. Watch BRISTOL-MYRS SQUIB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BRISTOL-MYRS SQUIB stocks are traded under the ticker BRM.
BRM stock has fallen by −7.11% compared to the previous week, the month change is a −6.02% fall, over the last year BRISTOL-MYRS SQUIB has showed a 14.84% increase.
We've gathered analysts' opinions on BRISTOL-MYRS SQUIB future price: according to them, BRM price has a max estimate of 63.34 CHF and a min estimate of 33.48 CHF. Watch BRM chart and read a more detailed BRISTOL-MYRS SQUIB stock forecast: see what analysts think of BRISTOL-MYRS SQUIB and suggest that you do with its stocks.
BRM reached its all-time high on May 13, 2022 with the price of 76.649 CHF, and its all-time low was 37.010 CHF and was reached on Jun 14, 2024. View more price dynamics on BRM chart.
See other stocks reaching their highest and lowest prices.
BRM stock is 7.66% volatile and has beta coefficient of −0.03. Track BRISTOL-MYRS SQUIB stock price on the chart and check out the list of the most volatile stocks — is BRISTOL-MYRS SQUIB there?
Today BRISTOL-MYRS SQUIB has the market capitalization of ‪101.86 B‬, it has decreased by −5.36% over the last week.
Yes, you can track BRISTOL-MYRS SQUIB financials in yearly and quarterly reports right on TradingView.
BRISTOL-MYRS SQUIB is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
BRM earnings for the last quarter are 1.52 CHF per share, whereas the estimation was 1.33 CHF resulting in a 14.12% surprise. The estimated earnings for the next quarter are 1.37 CHF per share. See more details about BRISTOL-MYRS SQUIB earnings.
BRISTOL-MYRS SQUIB revenue for the last quarter amounts to ‪11.21 B‬ CHF, despite the estimated figure of ‪10.51 B‬ CHF. In the next quarter, revenue is expected to reach ‪9.63 B‬ CHF.
BRM net income for the last quarter is ‪65.39 M‬ CHF, while the quarter before that showed ‪1.03 B‬ CHF of net income which accounts for −93.63% change. Track more BRISTOL-MYRS SQUIB financial stats to get the full picture.
Yes, BRM dividends are paid quarterly. The last dividend per share was 0.56 CHF. As of today, Dividend Yield (TTM)% is 4.33%. Tracking BRISTOL-MYRS SQUIB dividends might help you take more informed decisions.
As of Feb 24, 2025, the company has ‪34.10 K‬ employees. See our rating of the largest employees — is BRISTOL-MYRS SQUIB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRISTOL-MYRS SQUIB EBITDA is ‪16.79 B‬ CHF, and current EBITDA margin is 39.98%. See more stats in BRISTOL-MYRS SQUIB financial statements.
Like other stocks, BRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRISTOL-MYRS SQUIB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BRISTOL-MYRS SQUIB technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BRISTOL-MYRS SQUIB stock shows the neutral signal. See more of BRISTOL-MYRS SQUIB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.